Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Titer Levels in Pregnant Individuals After Infection, Vaccination, or Both

Obstet Gynecol. 2023 Jun 1;141(6):1199-1202. doi: 10.1097/AOG.0000000000005172. Epub 2023 May 3.

Abstract

We examined differences in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in pregnant individuals with natural, vaccine-induced, or combined immunity. Participants had live or nonlive births between 2020 and 2022, were seropositive (SARS-CoV-2 spike protein, anti-S), and had available mRNA vaccination and infection information (n=260). We compared titer levels among three immunity profiles: 1) natural immunity (n=191), 2) vaccine-induced immunity (n=37), and 3) combined immunity (ie, natural and vaccine-induced immunity; n=32). We applied linear regression to compare anti-S titers between the groups, controlling for age, race and ethnicity, and time between vaccination or infection (whichever came last) and sample collection. Anti-S titers were 57.3% and 94.4% lower among those with vaccine-induced and natural immunity, respectively, compared with those with combined immunity ( P <.001, P =.005).

MeSH terms

  • Antibodies, Viral
  • COVID-19 Vaccines* / administration & dosage
  • COVID-19* / prevention & control
  • Female
  • Humans
  • Pregnancy
  • Pregnancy Complications, Infectious* / prevention & control
  • SARS-CoV-2
  • Vaccination

Substances

  • Antibodies, Viral
  • spike protein, SARS-CoV-2
  • COVID-19 Vaccines